Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Center, shared a post on X about a paper by Thomas Chalopin et al. published in Blood Cancer Journal:
“Debulking before BsAb to high outcomes for RRMM
- n=44,50% EMD, HRCG, high BM Dx
- C/w historical cohorts, high ORR and PFS in EMD
- Need to define optimal debulking (low M-Prt, sFLC, PET SUV) and c/w matched control of no prior debulking.”
Title: Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Authors: Thomas Chalopin, Elise Cellerin, Hélène Demarquette, Andréa Pieragostini, Cécile Sonntag, Caroline Jaquet, Zoé De Wyngaert, Anne Rumpler, Murielle Roussel, Gaelle Labouré, Véronique Morel, Laure Vincent, Valéry Salle, Titouan Cazaubiel, Arthur Bobin, Anaïs Schavgoulidze, Jill Corre, Xavier Leleu, Salomon Manier
You can read the Full Article in Blood Cancer Journal.
More posts featuring Hamza Hashmi.
